A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
Daiichi Sankyo
Medical University of South Carolina
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
Dana-Farber Cancer Institute
Washington University School of Medicine
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ARCE Therapeutics, Inc.
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Chinese PLA General Hospital
Indapta Therapeutics, INC.
Thomas Jefferson University
Affiliated Hospital to Academy of Military Medical Sciences
Hoffmann-La Roche
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Baptist Health South Florida
Celgene
University Hospital Heidelberg
Arog Pharmaceuticals, Inc.
Columbia University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Washington University School of Medicine
Arog Pharmaceuticals, Inc.
Indiana University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
TCR2 Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Precision BioSciences, Inc.
PETHEMA Foundation